Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NUTEX InvestmentsBUD:NUTEX +1.96%18 Cash Ratio is 150.57 as of Dec. 2025, which is 26% below its 10-year median of 204.08. GuruFocus rates BUD:NUTEX with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 971 Drug Manufacturers companies, NUTEX Investments ranks better than 99.79% on this metric.
NUTEX Investments has a Cash Ratio of 150.57. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for NUTEX Investments's Cash Ratio or its related term are showing as below:
BUD:NUTEX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.07 Med: 204.08 Max: 876.26
Current: 150.57
During the past 13 years, NUTEX Investments's highest Cash Ratio was 876.26. The lowest was 0.07. And the median was 204.08.
BUD:NUTEX's Cash Ratio is ranked better than 99.79% of 971
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs BUD:NUTEX: 150.57
NUTEX Investments (BUD:NUTEX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
NUTEX Investments Cash Ratio Related Terms
NUTEX Investments Cash Ratio Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: Cash Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Cash Ratio distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUTEX Investments (BUD:NUTEX) has a Cash Ratio of 150.57 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on NUTEX Investments and its competitors. This is 26% below median its historical median of 204.08. Over the past decade, NUTEX Investments' Cash Ratio has ranged from 0.07 to 876.26. According to the industry distribution chart, NUTEX Investments ranks #2 out of 971 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is NUTEX Investments' Cash Ratio too high?
NUTEX Investments' current Cash Ratio of 150.57 is 26% below median its 10-year median of 204.08. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 876.26. The Drug Manufacturers industry median Cash Ratio is 0.59. NUTEX Investments' value of 150.57 is 25420.3% above this industry median. Based on the distribution chart, NUTEX Investments ranks #2 out of 971 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NUTEX Investments has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #2 out of 971 companies for Cash Ratio. This places NUTEX Investments in the top 0% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.59. NUTEX Investments' value of 150.57 is 25420.3% above this benchmark. Historically, NUTEX Investments' own Cash Ratio has ranged from 0.07 to 876.26 over the past decade. While the company's 10-year median is 204.08 vs. the industry median of 0.59, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.59, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current Cash Ratio of 150.57 is 25420.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Cash Ratio is 150.57, which is 26% below median its own 10-year median of 204.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
NUTEX Investments (BUD:NUTEX) has a current Cash Ratio of 150.57. The current Cash Ratio is 150.57, which is 26% below median its 10-year median of 204.08 and 25420.3% above the Drug Manufacturers industry median of 0.59. NUTEX Investments' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Cash Ratio is 150.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
18GF Score
Get the complete analysis for BUD:NUTEX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
